| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
IC50: antibacterial[1]
The primary target of sulfamonomethoxine sodium is dihydropteroate synthetase, an enzyme involved in the bacterial folate synthesis pathway. By inhibiting this enzyme, the compound blocks the synthesis of folic acid, which is essential for bacterial growth and replication. The compound acts as a competitive inhibitor of dihydrofolate synthesis, effectively disrupting the production of tetrahydrofolic acid. Its antibacterial activity is directed against both gram-positive and gram-negative bacteria, including Escherichia coli and Acinetobacter baumannii. |
|---|---|
| ln Vitro |
Sulfamonomethoxine sodium exhibits potent antibacterial activity in vitro against a variety of gram-positive and gram-negative bacteria. It is a long-acting sulfonamide that effectively inhibits bacterial growth by blocking folic acid synthesis. The compound's mechanism of action involves competitive inhibition of dihydropteroate synthetase, preventing the formation of dihydrofolate and subsequently tetrahydrofolate. It has been used in blood kinetic studies to evaluate its antibacterial efficacy and pharmacokinetic properties.
|
| ln Vivo |
In vivo activity of sulfamonomethoxine sodium has been evaluated in blood kinetic studies, where it is used as a competitive inhibitor of dihydrofolate synthesis. The compound demonstrates antibacterial efficacy in animal models of infection, although specific in vivo data are limited in the available literature. Its long-acting nature makes it suitable for studies requiring sustained antibacterial activity. Further in vivo investigations would be needed to fully characterize its efficacy against specific pathogens and its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for sulfamonomethoxine sodium typically involve measuring its inhibition of dihydropteroate synthetase activity. The assay uses bacterial cell extracts or recombinant enzyme to assess the compound's ability to compete with para-aminobenzoic acid (PABA) for binding to the enzyme's active site. Inhibition of enzyme activity is measured by quantifying the production of dihydrofolate or downstream products. The compound's IC50 value can be determined from dose-response curves generated in these enzymatic assays.
|
| Cell Assay |
In vitro cellular assays for sulfamonomethoxine sodium involve culturing susceptible bacterial strains (e.g., Escherichia coli or Staphylococcus aureus) in the presence of varying concentrations of the compound. Bacterial growth inhibition is assessed by measuring optical density at 600 nm (OD600) or by colony counting after overnight incubation. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that completely inhibits visible bacterial growth. These assays demonstrate the compound's broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria.
|
| Animal Protocol |
In vivo animal experiments for sulfamonomethoxine sodium typically involve administering the compound to infected animal models (e.g., mice or rats) via oral or intravenous routes. Blood samples are collected at various time points to measure drug concentrations and assess antibacterial efficacy. The compound's ability to inhibit bacterial growth in vivo is evaluated by measuring bacterial load in tissues or blood. These studies are used to determine the compound's pharmacokinetic properties and therapeutic potential.
|
| ADME/Pharmacokinetics |
Sulfamonomethoxine sodium exhibits pharmacokinetic properties typical of long-acting sulfonamides. The compound is administered orally and is absorbed from the gastrointestinal tract, achieving sustained plasma concentrations due to its long half-life. It is distributed throughout the body and is primarily eliminated via renal excretion. Blood kinetic studies are utilized to characterize its absorption, distribution, metabolism, and excretion profile. The compound's long-acting nature makes it suitable for sustained antibacterial therapy in research settings.
|
| Toxicity/Toxicokinetics |
Toxicological data for sulfamonomethoxine sodium are limited, as the compound is primarily intended for research and analytical applications. As a sulfonamide antibiotic, it may exhibit toxicity profiles similar to other members of this class, including potential for hypersensitivity reactions, renal toxicity, and hematological effects. Standard laboratory safety precautions should be followed when handling this compound. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Sulfamonomethoxine sodium (CAS#: 38006-08-5) is a sulfonamide antibacterial agent with the molecular formula C11H11N4NaO3S and molecular weight 302.29. It functions as a competitive inhibitor of dihydropteroate synthetase, blocking folic acid synthesis in bacteria. The compound is used as a reference standard in analytical research, quality control, and biochemical studies. It is effective against gram-positive and gram-negative bacteria and is intended for research use only.
|
| Molecular Formula |
C11H11N4NAO3S
|
|---|---|
| Molecular Weight |
302.28
|
| Exact Mass |
302.044
|
| CAS # |
38006-08-5
|
| Related CAS # |
Sulfamonomethoxine;1220-83-3
|
| PubChem CID |
656643
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
513.2ºC at 760 mmHg
|
| Flash Point |
264.2ºC
|
| LogP |
2.389
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IZJAOWYNDLDRKM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11N4O3S.Na/c1-18-11-6-10(13-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9;/h2-7H,12H2,1H3;/q-1;+1
|
| Chemical Name |
sodium;(4-aminophenyl)sulfonyl-(6-methoxypyrimidin-4-yl)azanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3082 mL | 16.5410 mL | 33.0819 mL | |
| 5 mM | 0.6616 mL | 3.3082 mL | 6.6164 mL | |
| 10 mM | 0.3308 mL | 1.6541 mL | 3.3082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
